Impaired Right, Left, or Biventricular Function and Resting Oxygen Saturation Are Associated With Mortality in Eisenmenger Syndrome: A Clinical and Cardiovascular Magnetic Resonance Study. by Jensen, AS et al.
Eisenmenger outcomes CIRCCVIM/2015/003596R2  Jensen, Broberg et al. 
 
1 
 
Impaired right, left or biventricular function and resting oxygen saturation 
are associated with mortality in Eisenmenger Syndrome: a clinical and 
cardiovascular magnetic resonance study. 
Annette S Jensen
 
MD PhD
1,2
, Craig S Broberg MD
 1,3
,  
Riikka Rydman MD PhD
1,4
, Gerhard-Paul Diller MD PhD MSc
1,5
, Wei Li MD
 
PhD
1
, 
Konstantinos Dimopoulos MD PhD MSc
1
, Stephen J Wort MD PhD
1
, Dudley J Pennell FRCP FMedSc
1
, 
*Michael A Gatzoulis MD MRCPH
 
PhD
1
,
 
Sonya V Babu-Narayan MB BS
 
BSc MRCP PhD
1 
 
1 NIHR Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation 
Trust, National Heart and Lung Institute, Imperial College London, UK 
2   Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. 
3   Adult Congenital Heart Program, Knight Cardiovascular Institute, Oregon Health &Science University 
Portland, Oregon, USA 
4   Section of Clinical Physiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, 
Stockholm, Sweden 
5   Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, 
University Hospital Muenster, Muenster, Germany. 
   The first and second author contributed equally  
Corresponding author: 
*Professor Michael A. Gatzoulis MD MRCPH PhD FACC FESC 
Adult Congenital Heart Centre and Centre for Pulmonary Hypertension  
NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, and the National Heart & 
Lung Institute, Imperial College, London, UK, 
Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK. 
Tel.: +44 20 73518602, Fax: +44 20 73518629, E-mail: m.gatzoulis@rbht.nhs.uk 
 
Conflicts of Interest:  
There are no relevant conflicts of interest. 
Funding Sources: 
Sonya V. Babu-Narayan is supported by an Intermediate Clinical Research Fellowship from the British 
Heart Foundation (FS/11/38/28864). This project was supported by the NIHR Cardiovascular Biomedical 
Research Unit of Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. 
This report is independent research by the National Institute for Health Research Biomedical Research 
Unit Funding Scheme. The views expressed in this publication are those of the author(s) and not 
necessarily those of the NHS, the National Institute for Health Research or the Department of Health. 
Craig Broberg was funded for this work by the Waring Trust, UK. Riikka Rydman was supported by the 
Swedish Society of Medicine, Swedish Heart-Lung Foundation and Swedish Society for Medical 
Research and by the section of Clinical Physiology, Department of Molecular Medicine and Surgery, at 
Karolinska Institute, Stockholm, Sweden.   
Subject codes: Diagnostic testing:30 CT and MRI, [41] Pediatric and congenital heart disease, 
including cardiovascular surgery [18] Pulmonary circulation and disease 
Word count: 5,745 
Eisenmenger outcomes CIRCCVIM/2015/003596R2  Jensen, Broberg et al. 
 
2 
 
Abstract 
Background: Patients with ES have better survival, despite similar pulmonary vascular 
pathology, compared to other patients with pulmonary arterial hypertension (PAH). 
Cardiovascular magnetic resonance (CMR) is useful for risk stratification in idiopathic PAH 
(IPAH), whereas it has not been evaluated in ES. We studied CMR together with other non-
invasive measurements in Eisenmenger syndrome (ES) in order to evaluate its potential role as a 
non-invasive risk stratification test. Methods and Results: Between 2003 and 2005, 48 ES 
patients, all with a post-tricuspid shunt, were enrolled in a prospective, longitudinal, single centre 
study. All patients underwent a standardized baseline assessment with CMR, blood test, 
echocardiography and 6 minute walk test (6MWT), and were followed for mortality until the end 
of December 2013. Twelve patients (25%) died during follow-up, mostly from heart failure 
(50%). Impaired ventricular function (right or left ventricular ejection fraction; RVEF, LVEF) 
was associated with increased risk of mortality (lowest quartile; RVEF<40%; HR=4.4 [95% CI 
1.4-13.5], p=0.01, lowest quartile; LVEF<50%; HR=6.6 [95% CI 2.1-20.8], p=0.001). 
Biventricular impairment (lowest quartile LVEF<50% and RVEF <40%) conveyed an even 
higher risk of mortality (HR=8.0 [95% CI 2.5-25.1], p=0.0004). No other CMR or non-invasive 
measurement besides resting oxygen saturation (HR=0.90 [0.83-0.97]/%, p=0.007) was 
associated with mortality. Conclusions: Impaired right, left or bi-ventricular systolic function 
derived from baseline CMR and resting oxygen saturation are associated with mortality in adult 
patients with ES. CMR is a useful non-invasive tool, which may be incorporated in the risk 
stratification assessment of ES during lifelong follow-up.  
Keywords: Eisenmenger syndrome, Cardiovascular Magnetic Resonance, ventricular 
impairment, ejection fraction, mortality. 
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Introduction 
Eisenmenger syndrome (ES) shares many aspects of the clinical and hemodynamic 
alterations as well as pulmonary microvascular changes with other forms of pulmonary arterial 
hypertension (PAH) 
1, 2
. However, ES patients seem to have a better prognosis compared 
especially with those with idiopathic PAH 
3, 4
. A common cause of death in patients with PAH, 
other than ES, is RV failure as a consequence of the inability of the RV to cope with increased 
afterload 
2, 5
 In ES, in contrast, it has been suggested that the RV is better adapted to increased 
afterload, having been exposed to volume and pressure overload since birth 
6, 7
. Furthermore, 
regression of the physiological right ventricular hypertrophy present at birth does not occur in 
some patients, particularly those with post-tricuspid shunts. Despite these potentially beneficial 
adaptive mechanisms, heart failure is not an uncommon cause of death in ES patients; 
furthermore, ES patients have a have significantly decreased life expectancy compared to healthy 
controls 
8-10
. Improved ability to estimate prognosis on an individual basis is needed for risk 
stratification, to assist with initiation of drug therapy, and subsequently for deciding about 
escalation of therapy and ultimately potentially listing for heart and lung transplantation. 
Cardiovascular magnetic resonance (CMR) has been implemented in the non-invasive evaluation 
of idiopathic PAH due to its superiority in assessing RV volumes and systolic function compared 
to echocardiography and its proven ability to predict mortality in prospective studies in both 
adults and children with various forms of PAH 
11-13
. In contrast, the value of CMR-derived 
assessment of cardiovascular function in ES remains unknown. We aimed to evaluate CMR in 
ES and its potential role in the non-invasive clinical risk assessment of ES patients.   
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Methods 
Patients and study design 
Consecutive, clinically stable adults with Eisenmenger physiology were invited to 
participate and underwent same day baseline investigations between 2003 and 2005. The study 
was conducted according to the declaration of Helsinki. The UK local research ethics committee 
approved the study [03-162][04-044]. All patients/guardians gave written informed consent prior 
to participation.  
Eisenmenger physiology was defined as a known intra-cardiac or extra-cardiac non-
restrictive defect, with increased pulmonary vascular resistance and reversed or bi-directional 
shunt resulting in hypoxemia 
14-15
. Patients with learning difficulties with capacity to consent and 
patients, whose parent or guardian gave consent on their behalf, were included.  Regarding 
defect and shunt location, only patients with a post-tricuspid defect were included. The well 
described different physiology, adaptation and timing of development of Eisenmenger syndrome 
between patients with underlying pre and post tricuspid shunts 
16
was the main reason for 
selecting only the latter patients for the study. Patients with unstable, decompensated heart 
failure, active hemoptysis, recent surgery and/or non-elective hospitalization, were excluded 
until stable and, then invited to participate at a later date after complete resolution of the acute 
event. Patients with relative contraindication to CMR at baseline including those with a 
permanent pacemaker or implantable cardioverter defibrillator were excluded. All patients were 
followed for mortality until the end of 2013. Deaths were identified from the hospital database, 
automatically updated by the Office for National Statistics, which registers all UK deaths. Cause 
of death was recorded for all patients. 
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Cardiovascular Magnetic Resonance (CMR) 
  CMR was performed using a 1.5 Tesla scanner (Sonata, Siemens, Erlangen, Germany) with 
a phased array body coil.  After routine assessment of anatomy, a short axis contiguous stack of 
steady state free precession cine images (7mm slices) from the atrioventricular ring to the apex 
was acquired for measurement of biventricular volumes and function. Volumes and ejection 
fraction for the RV and LV at end-diastole and end-systole, indexed to body surface area, were 
calculated by manually contouring the epi- and endocardial borders from short axis images.  
Contouring included trabeculations and papillary muscles as part of the myocardial mass and 
excluded them from the blood pool. All CMR measurements were made by one observer (CSB) 
and reported at the time of the baseline study.  For patients with a ventricular septal defect 
(VSD), delineation between the RV and LV chambers at the defect was done using a line in 
direct continuity with the septum. RV and LV wall stress index was calculated according to the 
formula: Systolic Blood Pressure (BP) x End-Systolic Volume index (ESVi)/ Mass index (Mi) 
17
. 
Late Gadolinium Enhancement (LGE) imaging (segmented fast low-angle shot inversion 
recovery sequence) was obtained 5-20 minutes after 0.1 mmol/kg IV gadolinium-DTPA 
administration in 30 of the 48 patients. Reasons for not performing LGE on all patients included 
patient factors (anxiety, inability to breath-hold and renal insufficiency) and logistical factors 
(scheduling), as previously reported 
18
.  Long axis acquisitions were also obtained as well as 
repeated short axis planes with altered direction of phase encoding to differentiate LGE from 
artifact.   
Other non-invasive investigations 
Venous blood was taken after 20 minutes supine rest for B- natriuretic peptides (BNP; 
monoclonal antibody assay, Shionoria, Schering, West Sussex, England) together with other 
routine bloods. All patients completed a 6-minute walk test (6MWT), and total walk distance 
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was recorded in metres. Protocolized  transthoracic echocardiography was performed as 
previously described 
15
 including tricuspid annular plane systolic excursion (TAPSE) (measured 
using M-mode recording of the RV free wall long axis motion from apical four-chamber view) 
and myocardial tissue Doppler velocities (obtained from the RV and LV free wall and septum by 
placing a tissue Doppler sample volume at basal part of respective segment in an apical four-
chamber view).  
Statistics 
Continuous data are summarized as mean (SD), whereas categorical data are given as N 
(%). The association between variables and event-free all-cause survival was tested using a Cox 
proportional hazards model, with results presented as hazard ratios and 95% confidence 
intervals. BNP and creatinine were log transformed due to skewed distribution. Due to the 
relatively small number of outcome events, we focused on uni- and bivariable analyses. Both, 
right ventricular (RVEF) and left ventricular ejection fraction (LVEF) were tested alongside 
other associated univariable parameters in a series of pair wise comparisons. Kaplan-Meier 
survival curves were used to illustrate survival prospects according to lower quartile of RVEF 
and LVEF, as well as lower quartile for both. Analysis was performed using SPSS version 22. A 
two-sided p-value of <0.05 was considered as statistical significant.  
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Results 
Baseline patient characteristics 
  Forty nine patients underwent a CMR as part of a protocolised study 
15
. One patient with 
isolated pre-tricuspid lesion was excluded from the analysis as per protocol and one patient did 
not complete the whole CMR examination (available data were included in the analysis). There 
were 28 women (58%), the mean age at inclusion was 40±14 years and 17% (n=8) of the patients 
had Down's syndrome. Underlying cardiac anatomy was: ventricular septal defect (n=31), 
atrioventricular septal defect (n=7), truncus arteriosus (n=7) and patent ductus arteriosus (n=3). 
Baseline CMR findings for the total population are summarised in Table 1. Of patients that 
underwent LGE CMR, 73% were LGE positive. Only one had LV LGE only. Of the 70% 
(21/30) with RV LGE, 53% (11/21) also had LV LGE. A strong correlation was observed 
between RVEF and LVEF (r=0.73, p<0.0001). 
Mortality 
Twelve patients (25%) died during follow-up. Cause of death was due to congestive heart 
failure (n=6), sudden death (n=2), haemoptysis (n=2), or other (n=2), respectively, Table 2.  
  Significant univariable factors associated with mortality were resting transcutaneous 
oxygen saturation (HR=0.90 [0.83-0.97]/%, p=0.007) as well as right (HR=0.96 [0.93-0.99]/%, 
p=0.02) and left ventricular ejection fraction (HR=0.94 [0.90-0.99]/%, p=0.01) measured by 
CMR, Table 3. These  remained significant even when non-cardiovascular causes (carcinoma 
and acute abdomen) were excluded (saturation:HR=0.87 [0.79-0.96]/%, p=0.004, 
RVEF:HR=0.95 [0.91-0.99]/%, p=0.01, LVEF: (HR=0.91 [0.86-0.97]/%, p=0.002) and even 
after further excluding death due to hemoptysis and including only patients whose death was 
sudden or due to heart failure (saturation: HR=0.88 [0.81-0.96]/%, p=0.004), RVEF: HR=0.96 
[0.92-0.99]/%, p=0.02), LVEF: HR=0.93 [0.88-0.98]/%, p=0.006). The Kaplan Meier survival 
curve stratified by the lower quartile for both RVEF (40%) and LVEF (50%) (RVEF Log-rank 
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p=0.0055; LVEF Log-rank p=0.0002) showed a significantly increased risk of death in ES 
patients with a RVEF below 40% or LVEF below 50%, Figure 1 and 2. Furthermore our study 
shows that biventricular impairment (patients in the lowest quartile of both LVEF [<50%] and 
RVEF  [<40%]) was associated with an even worse prognosis compared to impairment of only 
one ventricle (p=0.0001), Figure 3.   
The ejection fraction of both the RV and the LV was tested pairwise against resting 
oxygen saturation, the only other univariable association with mortality, in a bivariable Cox 
regression analysis. Both lower quartile RVEF (HR=4.4 [95% CI 1.4-13.5], p=0.01) and lower 
quartile LVEF (HR=6.6 [95% CI 2.1-20.8], p=0.001) remained independently associated with 
mortality in ES patients.  
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Discussion 
 
 This is the first study, to our knowledge, to report that CMR-derived indices of 
ventricular dysfunction are associated with mortality in patients with ES and post-tricuspid 
shunts. Systolic ventricular impairment, whether right or left, was associated with mortality in 
these patients. Furthermore, biventricular involvement was associated with even higher 
mortality.  
RV and LV ejection fraction are associated with mortality in Eisenmenger syndrome 
 Despite relatively better survival prospects amongst adults with ES, compared to other 
patients with PAH, life expectancy for those who make it to adulthood is shortened by 20 years if 
they have simple underlying cardiac defects and by 40 years, when cardiac anatomy is more 
complex 
19
. Identifying new markers associated with mortality is thus, both warranted and 
needed. CMR measures were recently shown to correlate with mortality, both in children and in 
adults with idiopathic PAH 
11-13
. Furthermore, RVEF derived from CMR was shown to be a 
stronger predictor of mortality than invasively measured pulmonary vascular resistance (PVR) in 
idiopathic PAH 
12,20,21
. In contrast, there were no CMR data to date relating to outcome for 
patients with ES. We have shown that CMR-derived RVEF correlates with mortality in ES 
patients, a finding previously shown in idiopathic PAH. In addition we found that LVEF was 
also associated with mortality which is in contrast to reported findings in the remaining PAH 
patient populations. Moreover, we found that if both ventricles are impaired the risk of death was 
highest.  
 Our patient sample was physiologically homogeneous relative to previous reports, as pre-
tricuspid shunt ES patients were excluded due to the influence of the presence and location of the 
shunt on right ventricular adaptation and hence natural history 
16
. CMR is recognized as the gold 
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standard for quantification of right (and left) ventricular volumes and function 
12
. It is also highly 
reproducible. It can be applied to accurately quantify ejection fraction without calculations based 
on geometrical assumptions, which is specifically relevant for assessing ES patients. Hence, it 
was possible to measure CMR derived indices of ejection fraction in all patients and no patient 
required exclusion due to complex underlying anatomy. Whilst, multiple factors are also likely to 
be relevant for prognostication in ES, we show here that CMR-derived right and left ventricular 
ejection fraction is associated with mortality. CMR may therefore, be a useful adjunct to resting 
transcutaneous oxygen saturation, echocardiography and BNP in the initial and ongoing follow-
up evaluation of ES patients. 
CMR derived ejection fraction in our ES study correlated with mortality, whereas previously 
reported clinically prognostic echocardiography and BNP measures did not reach statistical 
significance in the current study 
22-24
. The differences in findings may be explained by the 
smaller size in the current study, and the fact that previous studies also included ES patients with 
pre-tricuspid shunts who are physiologically different from the ES patients with post-tricuspid 
shunts 
16
. 
Ventricular dysfunction and interdependence in Eisenmenger syndrome 
 The presence of ventricular interdependence in the setting of congenital heart disease in 
general, and specifically in patients with ES, is well appreciated 
15,25
. In contrast to studies in 
idiopathic PAH, our study showed that increased mortality risk in ES patients related not only to 
right but also to left ventricular systolic dysfunction. In ES, commonly the post-tricuspid shunt 
causes shared volume and pressure load to both ventricles 
26
 which are comparable in size, 
whereas in other forms of pulmonary hypertension the pressure load is directed primarily 
towards the RV. Detrimental effects may therefore directly affect both ventricles in ES. This 
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ventricular interdependence, together with the fact that in ES the RV is primed to high pressure 
since birth 
6, 7
 may account for the superior survival, in ES compared to patients with other forms 
of pulmonary arterial hypertension. One could postulate that the RV is again relieved from high 
pressure with the onset of shunt reversal from right to left. When ventricular systolic dysfunction 
in ES ultimately ensues, it may be due to myocardial coronary insufficiency and/or 
maladaptation and may then progress rapidly 
5, 27
. Evidence of ventricular fibrosis from LGE 
study was more common in the RV but was also found in the LV. We submit that the onset of 
RV and LV dysfunction in ES is usually a late sign, associated with a guarded prognosis, which 
our data supports. 
Potential causes of ventricular dysfunction in Eisenmenger syndrome 
 In idiopathic PAH, patients respond initially to increased pulmonary pressure with 
adaptive RV hypertrophy. Right ventricular failure occurs when a hypertrophic response is 
exhausted and the RV instead begins to dilate; a mechanism some have called RV maladaptation. 
Histology in idiopathic PAH has demonstrated reduced capillary density, RV cardiomyocyte 
growth arrest and increased and marked RV fibrosis in the failing RV 
5, 27
. Few data exist 
regarding myocardial histology in the RV or LV in ES 
28, 29
. The relatively small number of ES 
patients studied with LGE CMR in our study and the quality of LGE acquisition during the era of 
the study may have underpowered it to detect possible associations of LGE with mortality. 
Although to date there are no data to demonstrate a positive link between LGE fibrosis and 
outcome in ES 
19
, this area warrants further exploration. Impairment of systolic ventricular 
function occurs in ES late, following a long initial adaptive ventricular response to volume with 
or without pressure overload and to cyanosis. To ascertain whether excessive hypertrophy or 
dilation was the underlying culprit for mortality similar to idiopathic PAH patients 
30, 31
 we 
calculated RV and LV wall stress index. We could not show that wall stress specifically was 
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associated with biventricular maladaptation in ES in this study. However we found that resting 
cyanosis was associated with mortality in keeping with a previous study showing that resting 
oxygen saturation below 85% was associated with a three-fold increase in mortality 
32
. Cyanosis 
may adversely affect ventricular function 
33, 34
 and its influence on the myocardium and other 
organ systems 
32, 35-38
 is both major and lifelong in ES. Whilst cyanosis and ventricular 
dysfunction were independently associated with mortality in our study it is feasible that they are 
also inter-related. 
Potential clinical implications for risk stratification in ES 
  A number of easily reproducible invasive and non-invasive clinical markers are used in 
the evaluation of PAH patients to predict mortality. European guidelines for PAH include a table 
adapted from McLaughlin and McGoon with parameters that can assist in the clinical evaluation 
of disease severity, stability and prognosis 
2
. Such parameters cannot be directly adopted in ES 
patients, who differ significantly from idiopathic PAH, both in terms of pathophysiology and 
outcome. An example of this is pericardial effusion in ES which to date does not appear to have 
an impact on mortality, yet is important in PAH 
24, 32
. It is likely that clinical risk stratification 
algorithms will not be confined to one parameter in this condition, similar to other PAH 
aetiologies. Our study suggests that CMR is useful as part of the armamentarium for clinical risk 
stratification of ES.   
Limitations 
 We confined our study to ES patients with post tricuspid shunts only to mitigate against 
heterogeneous underlying cardiac anatomy, early physiology and longer-term cardiovascular 
adaptation. The precise degree and mechanism to which the left or right ventricle share pressure 
and volume overload at different times may of course have varied. Not all patients are suitable 
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for CMR or can cooperate with current CMR algorithms; indeed one study patient failed to 
complete our CMR protocol.  
 A number of our ES patients were started on advanced therapy for PAH after their 
baseline assessment and, at variable times, which may well have been a cofounder. However, 
due to the time dependent nature of advanced therapy initiation, thereafter therapy changes and 
the fact that we only had access to a single, baseline CMR investigation, statistical adjustment 
for the effect of advanced therapies in this study is not possible. Further studies with repeated 
CMR assessment will be required to clarify this point.  
 Future and larger studies may validate our results and assess the potential for prognostic 
value of newer CMR biomarkers such as high resolution focal and diffuse myocardial fibrosis 
(more up to date 2D LGE optimised for more frail patients 
39
, 3D LGE 
40
 and T1 mapping 
techniques), and the potential to modify them with timely, advanced PAH therapy.  
Conclusion 
Impaired right, left and especially bi-ventricular systolic function derived from baseline 
CMR and resting oxygen saturations correlate with mortality in adult patients with ES due to 
post-tricuspid shunts. CMR is a useful non-invasive tool, which may be incorporated in the risk 
stratification assessment of ES during lifelong follow-up. 
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Figure legends 
Figure 1 
Kaplan-Meier survival curves with the survival distributions of patients with RVEF <40% (lower 
quartile cut-off)   
 
Figure 2  
Kaplan-Meier survival curves with the survival distributions of patients with LVEF <50% (lower 
quartile cut-off)   
 
Figure 3 
Kaplan-Meier survival curves with the survival distributions of patients with LV or RV 
impairment (defined as lower quartile EF) versus both RV and LV impairment.   
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Tables 
Table 1 Baseline characteristics of the Eisenmenger patients in the study   
 All patients (n=48) 
Age, years 40±14 
BSA, m
2 
1.6±0.2 
BMI, kg/m
2 22±4 
Down's syndrome, n (%) 8 (17) 
Male gender, n (%) 20 (42) 
NYHA ≥3, n (%) 17 (35) 
Heart rate, beats/min 82±14 
Previous arrhythmia, n (%) 11 (23) 
Cardiovascular magnetic resonance 
RVEDVi, mL/m
2 81±32 
RVESVi, mL/m
2 41±24 
RVEF, % 50±16 
RVMi, g/m
2 59±31 
RV wall stress index 94±56 
LVEDVi, mL/m
2 71±37 
LVESVi, mL/m
2 32±23 
LVEF, % 55±14 
LVMi, g/m
2 61±31 
LV wall stress index 79±48 
Max RAAi, cm
2
/m
2 14±4 
Max LAAi, cm
2
/m
2 10±4 
Fibrosis (LGE positive), n (%)* 22 (73) 
RV Fibrosis (LGE positive), n (%)* 21 (95) 
LV Fibrosis (LGE positive), n (%)* 12 (55) 
RV and LV fibrosis (LGE positive), n (%)* 11 (50) 
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Echocardiogram 
TAPSE, cm 17±4 
TDI RV systole (s’), cm/s 8±2 
TDI RV diastole (e’), cm/sec 6±3 
TDI LV systole (s’),  cm/s 8±2 
TDI LV diastole (e’), cm/sec 7±3 
Electrocardiogram 
QRS, ms 99±18 
6 minute walk test 
Oxygen saturation at rest, %  81±7 
6-minute walk distance, m 367±108 
Venous blood 
Hb, g/dL  19.7±2.9 
BNP, pmol/L 22±30 
Ferritin, µg/L 51±65 
Transferrin saturation, %   29±20 
Creatinine, µmol/L                           88±25 
BSA; Body Surface Area, BMI; Body Mass Index, NYHA; New York Heart Association functional class, 
CMR; cardiovascular magnetic resonance, RVEDVi; right ventricular end-diastolic volume index, 
RVESVi; right ventricular end-systolic volume index, RVEF; right ventricular ejection fraction, RVMi; 
right ventricular mass index, RV; right ventricle, RV wall stress  index (systolic blood pressure (BP) x 
RVESVi/RVMi), LVEDVi; left ventricular end-diastolic volume index, LVESVi; left ventricular end-
systolic volume index, LVEF; left ventricular ejection fraction, LVMi; left ventricular mass index, LV; 
left ventricle, LV wall stress  index (systolic blood pressure (BP) x LVESVi/LVMi), MaxRAAi; maximal 
right atrial areal index, Max LAAi; maximal left atrial areal index, LGE; late gadolinium enhancement, 
TAPSE; tricuspid annular plane systolic excursion, TDI; tissue doppler imaging, RV systole (s’); 
myocardial systolic velocity from basal RV free wall, RV diastole (e’); myocardial early diastolic velocity 
from RV free wall, LV systole (s’); myocardial systolic velocity from basal LV free wall, LV diastole 
(e’); myocardial early diastolic velocity from basal LV free wall, Hb; haemoglobin, BNP;  brain 
natriuretic peptide 
* Results based on a subset of 30 of the 48 patients. 
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Table 2 Cause of death in the Eisenmenger patient population 
Total number of deaths, n (%) 12 (25) 
Cardiac causes, n (%) 10 (83) 
- Heart failure, n (%)    6*(60) 
- Sudden cardiac death, n (%) 2 (20) 
- Haemoptysis, n (%) 2 (20) 
Non-cardiac causes, n (%) 2 (17) 
       -     Bladder Cancer, n (%) 1 (50) 
- Acute abdomen, n (%) 1 (50) 
*1 patient died during transplantation  
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Table 3 Univariate predictors of adverse clinical outcome in Eisenmenger patients  
Variable Hazard ratio (95% CI)       P 
Age at scan, yrs  1.04 (1.00-1.08)  0.08 
Male gender, n (%) 1.54 (0.47-5.08)  0.49 
Down's syndrome, present 0.95 (0.21-4.29) 0.95 
NYHA≥3 2.66 (0.85-8.36) 0.09 
Heart rate, beats/min 1.03 (0.99-1.08) 0.16 
Previous arrhythmia, presence 0.62 (0.08-4.75) 0.65 
RVEDVi, mL/m
2
 1.00 (0.98-1.02) 0.63 
RVESVi, mL/m
2
 1.00 (0.98-1.02) 0.89 
RVEF, % 0.97 (0.93-0.99) 0.02 
RVMi, g/m
2
 1.01 (0.98-1.04) 0.51 
RV wall stress index 1.00 (0.98-1.01) 0.61 
LVEDVi, mL/m
2
 1.01 (0.99-1.03) 0.44 
LVESVi, mL/m
2
 1.02 (1.00-1.05) 0.10 
LVEF, % 0.94 (0.90-0.99) 0.01 
LVMi, g/m
2
 1.02 (1.00-1.05) 0.06 
LV wall stress index 1.00 (0.98-1.02) 0.96 
MaxRAAi, cm
2
/m
2
 1.00 (1.00-1.00) 0.39 
MaxLAAi,  cm
2
/m
2
 1.00 (1.00-1.00) 0.19 
Fibrosis (LGE positive)* 0.88 (0.13-5.82) 0.90 
RV Fibrosis (LGE positive) * 0.47 (0.08-2.74) 0.47 
LV Fibrosis (LGE positive)* 2.50 (0.45-14.04) 0.30 
RV and LV fibrosis (LGE positive)
*
 1.41 (0.25-7.90) 0.70 
TDI RV systole (s’), cm/sec 1.05 (0.70-1.58)  0.82 
QRS, ms 1.01 (0.97-1.05) 0.61 
Oxygen saturation rest, % 0.90 (0.83-0.97) 0.007 
6-min walk distance, m 1.00 (0.99-1.00) 0.27 
Log(BNP), pmol/L 2.87 (0.69-11.95) 0.15 
Log(Creatinine), µmol/L 21.67 (0.20-2404.04) 0.20 
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NYHA; New York Heart Association functional class, RVEDVi; right ventricular end-diastolic volume 
index, RVESVi; right ventricular end-systolic volume index, RVEF; right ventricular ejection fraction, 
RVMi; right ventricular mass index, RV; right ventricle, RV wall stress  index (systolic blood pressure 
(BP) x RVESVi/RVMi), LVEDVi; left ventricular end-diastolic volume index, LVESVi; left ventricular 
end-systolic volume index, LVEF; left ventricular ejection fraction, LVMi; left ventricular mass index, 
LV; left ventricle, LV wall stress  index (systolic blood pressure (BP) x LVESVi/LVMi), MaxRAAi; 
maximal right atrial area index, MaxLAAi; maximal left atrial areal index, TAPSE; tricuspid annular 
plane systolic excursion, TDI; tissue doppler imaging, BNP; brain natriuretic peptide. 
* Results based on a subset of 30 of the 48 patients. 
 
 
 
 
